Buy DRTS by Sep 2, 2026.

I’ve been looking at DRTS after the Tolmar partnership, and I’m trying to separate the real signal from the usual small-cap biotech noise. The deal gives Alpha Tau funding, manufacturing support, and possible milestone payments, which is clearly helpful. But the more important part may be Tolmar’s commercial involvement. Tolmar already has experience in specialty pharma and urology-related markets, so this is not just a random outside investor. They seem to be making a targeted bet that Alpha DaRT could …